Pfizer. Pfizer hereby covenants that it shall not (and shall cause its Affiliates not to), during the Exclusivity Period, [***]. Notwithstanding the foregoing, the limitations set forth in this Section 2.5.1 shall not apply to any New Indication, subject to Section 2.6.
Pfizer. 8.1.1 Pfizer may, at its sole discretion, file, prosecute, maintain and enforce the Pfizer Background Patent Rights and Pfizer Program Patent Rights. Pfizer shall use commercially reasonable efforts to file, prosecute, maintain and enforce the Pfizer Program Patent Rights in those countries and territories in which Pfizer customarily pursues patent protection for products of similar market potential as the Product. At Pfizer’s request, Archemix shall cooperate with Pfizer in all reasonable respects in connection with such preparation, filing, prosecution and maintenance of such Pfizer Program Patent Rights, including but not limited to obtaining assignments to reflect chain of title consistent with the terms of this Agreement, gaining United States patent term extensions, supplementary protection certificates and any other extensions that are now or become available in the future wherever applicable to Pfizer Program Patent Rights. For purposes of clarity, notwithstanding anything to the contrary herein, Pfizer shall have no rights to prepare, file, prosecute and/or maintain any Patent Rights that are Archemix Background Patent Rights or Archemix Program Patent Rights.
Pfizer. Pfizer has been operating in Turkey since 1957 and produces nearly 75% of its total product line in Turkey, where it has around 1,000 employees and has conducted 143 clinical trials. • Pfizer has invested over $20 million in Turkey and has helped train more than 3,000 Turkish physicians. PepsiCo • As of February 2019, PepsiCo has six factories in Turkey and has invested over $200 million into the country's economy. • PepsiCo provides employment for over 43,000 people in Turkey. Major Turkish companies in the U.S. similarly include a number of Turkey's most significant firms. Xxxxxxx Xxxxxxxxxx • One of Turkey's leading industrial enterprises, Borusan Mannesmann produces steel products, pipes, and industrial goods. It has over 300 employees in its Houston Baytown Plant, which was a $150 million construction project and $328 million overall investment into the state of Texas. me Colakoglu Metalurji Qolakoglu Po u r Se a s o n s YILPORT HOLDINCi INC. CIMI AMERICAS 43* GO DIVA lie/fciurn 1926 • Colakoglu Metalurji is one of Turkey's major steel producers. In 2012, it founded its US subsidiary in Houston. • The company has made a $25 million investment into its American business. KordSA KordSA, a Turkish composites and tire reinforcements producer, has been in operating Tennessee, North Carolina, Pennsylvania, and California for over 15 years. The company has invested $487 million into its business in the U.S., where it has 750 employees. Four Seasons - The Surf Club • The Surf Club, a complex in Miami consisting of a hotel, restaurants, and private residences, was purchased by Koc Holding, the largest Turkish conglomerate, in 2012 for $116 million. This was followed by a $290 million development. Yilport Holdings In April 2018, Mississippi State Port Authority and Turkish firm Yilport Holdings signed an expansion deal as part of a $570 million restoration project. Yilport will invest in facilities and equipment upgrades as part of a lease agreement. CimSA Americas • Owned by Sabanci Holding, one of Turkey's largest industrial and business conglomerates, CimSA America produces cement and ready-mixed concrete. It has a production facility as well as a sales office in Houston. • CimSA has invested almost $60 million into the state of Texas, where it as over 20 employees.
Pfizer. PFIZER hereby represents and warrants to INHALE as follows:
Pfizer. (a) Notwithstanding anything to the contrary contained herein or in the *, Pfizer shall * results from a breach by Pfizer of its obligations under this Agreement, which breach remains uncured * following receipt by Pfizer of a notice of breach pursuant to Section 12.1(a) hereof.
Pfizer. For the attention of: Axxxxx X. Xxxxxxxx The registered office from time to time of Pfizer With a copy (not constituting notice) to: Jxxxx X. Xxxxx Xxxxxxxx, Lxxxxx, Rxxxx & Kxxx, 50 Xxxx 00xx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000 JXXxxxx@xxxx.xxx SLP1 For the attention of: Company Secretary of GSK The registered office from time to time of GSK cxxxxxx.xxx@xxx.xxx With a copy (not constituting notice) to: Cxxxxx Xxxxxxx Sxxxxxxxx and May, One Bunhill Row, London EC1Y 8YY cxxxxx.xxxxxxx@xxxxxxxxxxxxxxx.xxx SLP2 For the attention of: Company Secretary of GSK The registered office from time to time of GSK cxxxxxx.xxx@xxx.xxx With a copy (not constituting notice) to: Cxxxxx Xxxxxxx Sxxxxxxxx and May, One Bunhill Row, London EC1Y 8YY cxxxxx.xxxxxxx@xxxxxxxxxxxxxxx.xxx SLP3 For the attention of: Company Secretary of GSK The registered office from time to time of GSK cxxxxxx.xxx@xxx.xxx With a copy (not constituting notice) to: Cxxxxx Xxxxxxx Sxxxxxxxx and May, One Bunhill Row, London EC1Y 8YY cxxxxx.xxxxxxx@xxxxxxxxxxxxxxx.xxx GSK Bank Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB exxxxxx.xxxxxxx@xxxx.xxx With a copy (not constituting notice) to: Equity Syndicate Desk; Jxxxx Xxxxxxx Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB
Pfizer. (i) Pfizer shall use Commercially Reasonable Efforts to Develop, seek Marketing Approval, and where necessary, Pricing Approval for [*]; provided that should Pfizer terminate this Agreement pursuant to Section 12.2(a) with respect to (A) [*], then in lieu of using Commercially Reasonable Efforts in the U.S., Pfizer shall use Commercially Reasonable Efforts to Develop, seek Marketing Approval, and where necessary, Pricing Approval for [*] in one non-terminated country in [*], (B) [*], then in lieu of using Commercially Reasonable Efforts in [*] in one non-terminated country in [*], or (C) [*], then in lieu of using Commercially Reasonable Efforts in the [*], Pfizer shall use Commercially Reasonable Efforts to Develop, seek Marketing Approval, and where necessary, Pricing Approval for [*] in one non-terminated country in [*].
Pfizer. Pfizer shall itself, or through its Affiliates or sublicensees, use Commercially Reasonable Efforts to Commercialize [***].
Pfizer. Subject to Section 7.5, Pfizer shall pay to Licensee non-refundable, non-creditable royalties in the amount of the flat royalty rate (set forth below) (“Pfizer Royalty Rate”) on the aggregate Net Sales resulting from the sale of Products, on a Product-by-Product basis, in the ROW during each Pfizer Year (collectively, “Pfizer Royalties”). ROW NET SALES PFIZER ROYALTY RATE [***] [***] Pfizer shall pay to Licensee the applicable Pfizer Royalties within [***] following the expiration of each Pfizer Quarter after the date of the First Commercial Sale in the ROW. All Pfizer Royalty payments shall be accompanied by a report that includes reasonably detailed information regarding a total monthly sales calculation of Net Sales of Product in the ROW and all Pfizer Royalties payable to Licensee for the applicable Pfizer Quarter (including any foreign exchange rates employed). Pfizer Royalties will be payable on a Product-by-Product and country-by-country basis during the Royalty Term for such Product in each country until the expiration of the Royalty Term for such Product in such country in the ROW. For purposes hereof, Net Sales during the Royalty Term for each Product in the ROW include sales of such Products that occur after the expiration of the Royalty Term or termination of this Agreement where the Manufacture, use or other Exploitation of such Products was Covered by a Valid Claim of a Licensed Patent Right during the Royalty Term.
Pfizer. Subject to the terms and conditions of this Agreement, Pfizer will indemnify, defend and hold harmless Neurocrine and its Affiliates, (each, a "Neurocrine Indemnified Party") from and against any and all Liability (as defined below) which:
